Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
NET REVENUE
Clinical testing	$ 222,015	$ 98,595	$ 86,408
Pharma services	22,068	1,207	661
Total Revenue	244,083	99,802	87,069
Cost of revenue	133,704	56,046	46,355
GROSS MARGIN	110,379	43,756	40,714
Operating expenses:
General and administrative	75,782	33,631	23,808
Research and development	4,649	4,198	2,689
Sales and marketing	23,910	11,562	11,999
Impairment charges	3,464
Total operating expenses	107,805	49,391	38,496
INCOME (LOSS) FROM OPERATIONS	2,574	(5,635)	2,218
Interest expense and debt termination fees, net	9,998	854	985
Other income		(2,000)	(56)
Income (loss) before taxes	(7,424)	(4,489)	1,289
Income tax (benefit) expense	(1,701)	(1,954)	157
NET INCOME (LOSS)	(5,723)	(2,535)	1,132
Deemed dividends on preferred stock	18,011	40
Amortization of preferred stock beneficial conversion feature	6,663	82
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (30,397)	$ (2,657)	$ 1,132
NET EARNINGS (LOSS) PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.39)	$ (0.04)	$ 0.02
Diluted	$ (0.39)	$ (0.04)	$ 0.02
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	77,542	60,526	53,483
Diluted	77,542	60,526	56,016